| Nov 6 |
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
|
| Oct 30 |
Revisiting Humacyte
|
| Oct 28 |
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
|
| Oct 25 |
High Growth Tech Stocks to Watch in October 2024
|
| Oct 23 |
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
|
| Oct 16 |
‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab
|
| Oct 8 |
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
|
| Oct 8 |
Humacyte Launches $30M Stock and Warrants Offering
|
| Oct 4 |
Humacyte prices $30M securities offering
|
| Oct 4 |
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
|
